Outcome of renal transplantation in children with low urinary tract abnormality.
BACKGROUND
Patients with end-stage renal disease and lower urinary tract abnormality are often considered high risk for renal transplantation.


METHODS
To examine the degree of risk, we studied patients who received renal transplants between 1985 and 2003. Forty eight patients had congenital lower urinary tract anomalies and 168 patients comprised a control group without these anomalies.


RESULTS
Mean age and distribution of sex were not significantly different between the case and the control group. Among patients with anomalies, 8% had delayed graft function; 75%, acute rejection; and 39.5%, chronic rejection. Among the controls 2.3% had delayed graft function; 59%, acute rejection; and 35%, chronic rejection. None of these differences was significant. Mean survival time was 6 years in affected patients and 7.3 years in the control group (P = .7). Among patients with anomalies the rate of graft survival in the first year after transplantation was 90%; and those in the third, fifth, and seventh years, 76%, 65%, and 40%, respectively. For the controls, the graft survivals were 88% at 1 year; 73% at 3 years; 70% at 5 years; and 49% at 7 years after transplantation.


CONCLUSIONS
This study showed that a history of lower urinary tract anomalies had no effect on graft function. Graft survival was not different among these patients compared with patients free of these anomalies.
Otukesh
H
H
Labafi Nejad Hospital, Pasdaran Avenue, Tehran, Iran. hasanotukesh@yahoo.com
Sharifian
M
M
Simfroosh
N
N
Basiri
A
A
Hoseini
R
R
Sedigh
N
N
Golnari
P
P
Rezai
M
M
Fereshtenejad
M
M
D000208:Acute Disease; D002648:Child; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014551:Urinary Tract / Q000002:abnormalities*
D007166:Immunosuppressive Agents; D003404:Creatinine